Greg Browne, Cyberonics' Chief Financial Officer, will present at the UBS Global Life Sciences Conference on Wednesday, September 19, 2012 at 3:00 PM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on September 19, 2012.
Mr. Browne will also present at the Credit Suisse 3rd Annual Small and Mid-Cap Conference on Thursday, September 20, 2012 at 4:30 PM Eastern Time. The conference sessions will not be webcasted and no slides will be presented at the conference.
About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.